Ultragenyx Pharmaceutical Inc.RAREEarnings & Financial Report
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
RARE Q3 2025 Key Financial Metrics
Revenue
$159.9M
Gross Profit
N/A
Operating Profit
$-170.9M
Net Profit
$-180.4M
Gross Margin
N/A
Operating Margin
-106.9%
Net Margin
-112.8%
YoY Growth
14.7%
EPS
$-1.81
Financial Flow
Ultragenyx Pharmaceutical Inc. Q3 2025 Financial Summary
Ultragenyx Pharmaceutical Inc. reported revenue of $159.9M for Q3 2025, with a net profit of $-180.4M (-112.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $159.9M |
|---|---|
| Net Profit | $-180.4M |
| Gross Margin | N/A |
| Operating Margin | -106.9% |
| Report Period | Q3 2025 |
Ultragenyx Pharmaceutical Inc. Annual Revenue by Year
Ultragenyx Pharmaceutical Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $560.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $560.2M |
| 2023 | $434.2M |
| 2022 | $363.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $127.4M | $108.8M | $147.0M | $139.5M | $164.9M | $139.3M | $166.5M | $159.9M |
| YoY Growth | 23.3% | 8.3% | 35.7% | 42.3% | 29.4% | 28.0% | 13.2% | 14.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.49B | $1.31B | $1.62B | $1.54B | $1.50B | $1.31B | $1.31B | $1.19B |
| Liabilities | $1.22B | $1.17B | $1.19B | $1.18B | $1.24B | $1.16B | $1.15B | $1.17B |
| Equity | $275.4M | $140.3M | $432.4M | $346.8M | $255.3M | $144.2M | $151.3M | $9.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-83.9M | $-190.7M | $-77.0M | $-67.0M | $-79.5M | $-166.5M | $-108.3M | $-91.4M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M